MOTIVATION LETTER The Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, directly addresses a critical gap in military medical readiness: the absence of a prophylactic intervention against opioid use disorder and stress-induced relapse. My three sole-authored preprints, including the formal mathematical specification (OSF 10.17605/OSF.IO/EMY4U) and Bayesian population dynamics architecture (Zenodo 10.5281/zenodo.20492472), demonstrate an 85.8 percent reduction in encoding probability from 0.855 to 0.122, with super-additivity of 12.8 percentage points across all five pre-registered hypotheses. These results were validated using ODE/RK45 and Bayesian MCMC methods, establishing a rigorous computational foundation for a pharmacological strategy that could prevent addiction before it consolidates. I am an independent researcher based in Lagos, Nigeria, holding a B.Pharm from the University of Ibadan with a German-equivalent grade of 1.9. My work has received endorsements from Kent Berridge at the University of Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at New York University. Gershman provided my arXiv endorsement. A provisional patent on the CCT core architecture is scheduled for Q3 2026. A review article is under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper is under review at Alcohol (Elsevier). The DoW Peer Reviewed Medical Discovery Award offers a unique opportunity to translate this framework from computational validation toward preclinical testing. My perspective as a Nigerian researcher adds a dimension of global health security: low-cost, scalable interventions developed in resource-limited settings can be deployed rapidly across diverse military populations. The CCT model, built entirely with open-source tools including Python, PyMC, and Gudhi, is designed for reproducibility and low-barrier adoption. I seek funding to extend the Bayesian population dynamics simulations into a multi-compartment pharmacokinetic-pharmacodynamic model parameterized for opioid agonists, and to develop a clinical trial simulation protocol ready for IRB submission. This work will be conducted independently, with computational infrastructure already established through ZYCO and my GitHub repository. The award would support publication fees, HPC compute time, and travel to present at the Society for Neuroscience annual meeting. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model addresses a fundamental question in addiction neuroscience: can reward-memory encoding be prevented pharmacologically before it becomes a consolidated behavioral pattern? Current interventions target established addiction through abstinence, substitution, or aversion. The CCT model proposes a prophylactic alternative by defining a tripartite threshold at which dopamine, glutamate, and norepinephrine signaling converge to trigger long-term potentiation in the nucleus accumbens and hippocampus. Below this threshold, the reward event is encoded but not consolidated; above it, a persistent memory trace forms. The model is specified mathematically in my second preprint (OSF 10.17605/OSF.IO/EMY4U) as a system of coupled ordinary differential equations representing neurotransmitter dynamics, solved via RK45 with adaptive step sizing. The Bayesian population dynamics framework (Zenodo 10.5281/zenodo.20492472) uses MCMC sampling with PyMC to estimate posterior distributions over threshold parameters across a simulated population of 10,000 virtual subjects. Results confirm all five pre-registered hypotheses: encoding probability reduction of 85.8 percent, super-additivity of 12.8 percentage points when all three neurotransmitter systems are modulated simultaneously, and dose-response monotonicity across a 4-log range. The translational pathway proceeds through three phases. Phase one, computational refinement, will extend the current ODE model to a full physiologically-based pharmacokinetic model incorporating absorption, distribution, metabolism, and excretion parameters for three candidate drug classes: a D1 receptor partial agonist, an mGluR2/3 positive allosteric modulator, and an alpha-2 adrenergic agonist. Phase two, in silico clinical trial simulation, will use the Bayesian framework to optimize dosing regimens and identify biomarker thresholds for patient stratification. Phase three, protocol development, will produce a complete clinical trial design for a double-blind, placebo-controlled, randomized study in a stress-induced reinstatement paradigm. This work is directly relevant to the DoW Peer Reviewed Medical program's mission to address military medical challenges. Opioid use disorder rates among service members remain elevated, and stress-induced relapse is a documented threat to operational readiness. A prophylactic intervention that prevents reward-memory consolidation could be administered prior to high-risk exposures, such as post-surgical opioid prescriptions or combat-related stress events. The CCT model's mathematical rigor and pre-registered validation provide a foundation for translation that is both credible and reproducible. My independent research track record, including three preprints, two papers under review, a provisional patent, and endorsements from four leading computational neuroscientists, demonstrates the capacity to execute this program without institutional infrastructure. The Africa/Nigeria angle is not incidental: low-cost, scalable pharmacological interventions developed in resource-limited settings can be deployed globally, including in forward-deployed military environments where supply chains are constrained. BUDGET NARRATIVE Requested funds will support three specific activities over a 12-month period. First, HPC compute time for Bayesian MCMC simulations and ODE parameter sweeps: 8,000 USD. This covers 200,000 core-hours on a SLURM-managed cluster, sufficient to run the full multi-compartment PK-PD model across 50,000 virtual subjects with 10,000 MCMC iterations each. Second, open-access publication fees for two peer-reviewed manuscripts: 6,000 USD. The foundational CCT paper and the clinical trial simulation protocol will be submitted to journals indexed in PubMed and Scopus. Third, travel and registration for the Society for Neuroscience annual meeting: 4,000 USD. This includes airfare from Lagos, five nights accommodation, and registration fees. Total requested: 18,000 USD. No salary or stipend is requested. Computational infrastructure, including Python, PyMC, Gudhi, and RDKit, is already installed and operational on my personal workstation and cloud instances. All software is open-source and Apache 2.0 licensed. The provisional patent filing costs are covered separately through ZYCO. BIOGRAPHICAL SKETCH Eniola Ayodele Olutogun. B.Pharm, University of Ibadan, 2021. CGPA 5.1/7.0, German equivalent 1.9. Licensed pharmacist, Pharmacists Council of Nigeria. Independent research, 2025-present. Developed the Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention in addiction. Three sole-authored preprints on OSF and Zenodo. Review article under review at Neuroscience and Biobehavioral Reviews. Co-authored paper under review at Alcohol (Elsevier). Provisional patent on CCT core architecture, Q3 2026. Platforms built: IMPRINT (addiction-liability screening), TOPOLOGIX (topological data analysis for drug-protein interaction using persistent homology and bipartite simplicial complexes, hERG cardiotoxicity MVP), GATE (BCI neural-stimulation safety evaluation, Apache 2.0). Employment: National Product Manager, Synthcare, March 2026-present. Clinical Pharmacist, Ramset Pharmacy, January-March 2026. Research Assistant, CDDDP (NMDA/insulin docking). Bioinformatics Researcher, GHRU-GSAR (antimicrobial resistance genomics, surveillance pipeline). Endorsements: Kent Berridge (University of Michigan), Samuel Gershman (Harvard University, arXiv endorsement), Nathaniel Daw (Princeton University), Marcelo Mattar (New York University). Technical skills: Python (scipy, numpy, ODE/RK45, PyMC/MCMC, pandas), R, TDA (Ripser, Gudhi), NEURON/Brian2, AlphaFold, RDKit, ADMET/QSAR, GROMACS, AutoDock, Nextflow/SLURM/HPC, Supabase/Postgres, JavaScript/Node.js. ORCID: 0009-0001-9272-6735. GitHub: github.com/AmunRaPtah. ZYCO: zyco.org. CHECKLIST - [ ] Complete Grants.gov registration for Eniola Ayodele Olutogun as individual applicant - [ ] Obtain DUNS number or Unique Entity Identifier (UEI) for individual researcher - [ ] Upload motivation letter as PDF, 500 words maximum - [ ] Upload research statement as PDF, 600 words maximum - [ ] Upload budget narrative as PDF, 300 words maximum - [ ] Upload biographical sketch as PDF, 2 pages maximum - [ ] Attach ORCID iD and GitHub profile URLs - [ ] Attach links to three preprints on OSF and Zenodo - [ ] Attach letter of endorsement from Samuel Gershman or Kent Berridge (confirm willingness) - [ ] Attach provisional patent filing receipt or confirmation number (Q3 2026, verify status) - [ ] Confirm eligibility for early-career researcher track under DoW Peer Reviewed Medical program - [ ] Verify deadline: July 30, 2026, 11:59 PM Eastern Time EDITOR NOTES - Eligibility risk: The DoW Peer Reviewed Medical Discovery Award typically requires an organization to submit on behalf of the applicant. Confirm whether individual independent researchers are eligible or if a sponsoring institution is required. If needed, identify a Nigerian university or research institute willing to serve as the applicant organization. - Fact verification: The provisional patent filing is listed as Q3 2026. Confirm the exact filing date and serial number before submission. If not yet filed, note that the application can reference a pending filing but must not claim a granted patent. - Gap: The profile does not include a specific military or veteran population connection. Strengthen the application by adding one sentence about collaboration with a military medical researcher or access to a relevant dataset. If none exists, consider reaching out to a Nigerian military medical officer for a letter of support. - Gap: No publication in a peer-reviewed journal is listed as accepted. Two papers are under review. The application should acknowledge this honestly and frame the preprints as evidence of rigorous pre-registration and open science practice. - Budget note: The total requested amount of 18,000 USD is below the typical Discovery Award range. Confirm the program's minimum and maximum award amounts. If the program expects larger budgets, consider adding a stipend for a research assistant or a small equipment purchase to reach a more competitive total.